B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.